Bottom line
Human body-composition evidence suggests that GLP-1-based weight-loss treatment can reduce both fat mass and lean mass. In the SURMOUNT-1 DXA substudy, most weight lost with tirzepatide was fat mass, but about a quarter was lean mass.
That does not mean the medicine is “muscle wasting” in a simple or sensational way. It means clinics should not talk only about scale weight.
A serious provider should be able to explain what it monitors, how it discusses nutrition and activity support, and when a patient needs review rather than another automatic prescription.
What human evidence shows
The clearest direct body-composition signal comes from studies that used DXA or similar methods, not before-and-after photos or marketing claims.
In a SURMOUNT-1 body-composition substudy, 160 participants with obesity or overweight had DXA measurements at baseline and week 72. In the pooled tirzepatide group, body weight fell by 21.3%, fat mass by 33.9%, and lean mass by 10.9%. The authors reported that roughly 75% of the weight lost was fat mass and roughly 25% was lean mass, with similar proportions in the placebo group.
A 2026 systematic review and network meta-analysis looked across randomised trials of GLP-1 receptor agonist-based medicines with direct body-composition measurements. That kind of review is useful because it does not rely on scale weight alone. The broad point for patients is simple: body composition is a real measurement issue, and different medicines, populations, study designs, and durations can produce different patterns.
What this does not prove
This evidence does not prove that everyone on GLP-1 or tirzepatide treatment loses clinically important muscle. It does not tell you whether treatment is right for an individual person. It does not prove that a particular diet, exercise plan, supplement, scan, or clinic package prevents lean-mass loss.
It also does not justify scare-marketing. Losing some lean mass during weight loss is not unique to GLP-1 medicines. The useful question is whether a clinic recognises the issue and responds with sensible assessment and follow-up rather than ignoring it or using it to upsell unsupported add-ons.
Why scale-only marketing is weak
A clinic can advertise impressive weight-loss percentages and still leave patients without enough context. Scale weight is easy to market. Body composition, strength, function, side effects, nutrition adequacy, and long-term maintenance are harder to manage.
That is why weight-loss evidence should lead to care-model questions. If a clinic frames success only as “lose X kg” or “drop X% body weight,” ask what else it tracks and what support sits around the prescription.
Questions to ask a clinic
- Do you discuss possible fat-mass and lean-mass changes before treatment starts?
- What do you monitor besides scale weight?
- How do you assess whether weight loss is too fast, poorly tolerated, or accompanied by weakness, low intake, or other concerns?
- What nutrition and activity support is included, and who provides it?
- Do you have a review process before continuing, pausing, escalating, or changing treatment?
- How do you handle older adults, people with frailty risk, previous eating-disorder history, or complex medical histories?
- Are body-composition scans used, and if so, how are their limits explained?
How to read clinic claims
Fair wording would say that body-composition monitoring can matter during GLP-1-based weight loss, and that public human evidence shows fat mass and lean mass can both change.
Weaker wording jumps further than the evidence. Be cautious with claims that a clinic can “protect all muscle,” “guarantee fat-only loss,” or solve the issue with a proprietary supplement stack. Those are stronger claims than the evidence usually supports.
Sources
- Perreault L, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025. DOI: 10.1111/dom.16275. PubMed
- Su X, et al. Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measurement of Body Composition Among Adults With Overweight or Obesity With or Without Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70884. PubMed
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. DOI: 10.1001/jama.2023.24945. PubMed
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553-1564. DOI: 10.1111/dom.14725. PubMed
Where to go next
This article pairs with GLP-1 Clinics: The WHO Guideline Shows What Smart Patients Should Ask and Weight Regain After Stopping GLP-1 Treatment. Together, the theme is the same: compare clinics by the quality of assessment, monitoring, maintenance planning, and evidence explanation — not by the biggest headline number.